Weiming Li
Chinese Academy of Sciences(CN)Hefei Institutes of Physical Science(CN)Institute of Plasma Physics(CN)Huazhong University of Science and Technology(CN)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Click Chemistry and Applications
Most-Cited Works
- → Epstein barr virus encodes miRNAs to assist host immune escape(2020)32 cited
- → Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials(2020)26 cited
- → The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data(2021)19 cited
- → Comparison of outcomes of idarubicin intensified TBI–CY and traditional TBI–CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience(2015)14 cited
- → A Novel Risk Predictive Scoring Model for Predicting Subsequent Infection After Carbapenem-Resistant Gram-Negative Bacteria Colonization in Hematological Malignancy Patients(2022)11 cited
- → Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation